Pharmos’ dexanabinol (correction)
Pharmos' Phase III trial for its cannabinoid dexanabinal in traumatic brain injury has completed projected enrollment of about 860 patients in the U.S. and other countries; results are expected by year-end. FDA placed the NMDA antagonist on fast track status in September 2003. Dexanabinol has never been in clinical development for Parkinson's disease or Alzheimer's disease as suggested in the 1March 22 issue of "The Pink Sheet" (p. 38)...
You may also be interested in...
Novartis' and Cephalon's disease-modifying Parkinson's disease agents are approaching the final stages of development, with at least one pivotal trial slated to begin in 2004
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.